Saitama Medical University · Faculty of Medicine / Graduate School of Medicine · 助教

Research keywordsanti-PD-1 therapy・CD4 T-cell immunity・non-small cell lung cancer・durvalumab management・immune-related adverse events・nivolumab retreatment

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer
• Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
• Detection of pseudoprogression with [ 18 F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment
• Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib

• 2020/04～2021/03 免疫チェックポイント阻害薬の適切な投与間隔・期間、有害事象回避のアルゴリズム開発 免疫チェックポイント阻害薬の適切な投与間隔・期間、有害事象回避のアルゴリズム開発2020 · 研究課題・受託研究・科研費
• 進行非小細胞肺癌における免疫チェックポイント阻害剤の新たなbiomarker探索を目指した18F- FDG PETへのdeep learning適用の検討
• 免疫チェックポイント阻害薬の適切な投与間隔・期間、有害事象回避のアルゴリズム開発

• Official profile